Abstract
Diabetic nephropathy is the leading cause of end-stage renal disease. Novel preventive measures for diabetic renal complications are urgently needed. Miyazaki et al. report that rosiglitazone, a thiazolidinedione insulin sensitizer and a potent peroxisome proliferator-activated receptor gamma agonist, not only effectively improves glycemic control but also halts progression of albuminuria in type 2 diabetic patients with early-stage diabetic nephropathy. These findings could offer a new prevention of diabetic nephropathy in insulin-resistant diabetic patients.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Albuminuria / etiology
-
Albuminuria / prevention & control
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / metabolism
-
Diabetic Nephropathies / blood
-
Diabetic Nephropathies / complications
-
Diabetic Nephropathies / prevention & control*
-
Glucose / metabolism
-
Humans
-
Hypoglycemic Agents / therapeutic use
-
PPAR gamma / agonists
-
Rosiglitazone
-
Thiazolidinediones / therapeutic use*
Substances
-
Hypoglycemic Agents
-
PPAR gamma
-
Thiazolidinediones
-
Rosiglitazone
-
Glucose